Undisclosed CDK12 inhibitor
/ Pear Bio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 26, 2025
Novel CDK12 inhibitors with preclinical anti-tumor activity and best-in-class profile on HER2 low breast cancer patient samples
(AACR 2025)
- P | "Our lead compounds have been assessed and carefully selected using our precision medicine platform to highlight drug molecules that can treat fresh tumor samples as a monotherapy and in combination with standard of care therapeutics. These molecules will be investigated further to nominate a development candidate and commence IND-enabling studies."
Preclinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • BRCA1 • BRCA2 • CDK4 • CDK6 • HER-2 • RAD51
1 to 1
Of
1
Go to page
1